Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00472992 · ClinicalTrials.gov registry record

Pregnancy Exposure Registry for Tysabri®

A clinical trial of Multiple Sclerosis and Pregnancy, sponsored by Biogen.

Completed
Registry status
376
Enrollment target
1
Study location

NCT00472992 is a study of Multiple Sclerosis and Pregnancy that has completed, run by Biogen. The registered enrollment target is 376 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00472992, a study of Multiple Sclerosis and Pregnancy, has completed, sponsored by Biogen.

COMPLETED
Registry status
376 participants
Enrollment target
1
Study location

Study Summary

The primary objective of the Registry was to evaluate the outcomes of pregnancy in women with Multiple Sclerosis (MS) or Crohn's Disease (CD) who were exposed to TYSABRI® at any time within 90 days prior to first day of Last Menstrual Period (LMP) or during pregnancy.

Study Locations (1)

West Virginia

  • United BioSource Corporation - Morgantown

Trial Details

FieldValue
Enrollment Target 376 participants
Start Date 2007-01
Est. Completion 2012-07

Sponsor

Biogen

334 total trials

What the Registry Record Tells You About NCT00472992

The ClinicalTrials.gov registry entry for NCT00472992 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (36% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT00472992 reports 1 study location spanning 1 distinct geographic area - top geographies include West Virginia.

Frequently Asked Questions

What is clinical trial NCT00472992 about?

NCT00472992 is a clinical study titled "Pregnancy Exposure Registry for Tysabri®". The primary objective of the Registry was to evaluate the outcomes of pregnancy in women with Multiple Sclerosis (MS) or Crohn's Disease (CD) who were exposed to TYSABRI® at any time within 90 days prior to first day of Last Menstrual Period (LMP) or during pregnancy.

What is the current status of trial NCT00472992?

This trial is currently completed. The enrollment target is 376 participants. The study started on 2007-01. Estimated completion is 2012-07.

What conditions does trial NCT00472992 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Pregnancy, Crohn's Disease, Prenatal Exposure.

Who is sponsoring clinical trial NCT00472992?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00472992 being conducted?

This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.